Hahn, Andrew W.
Thoman, Whittney
Koutroumpakis, Efstratios
Abdulla, Amer
Subudhi, Sumit K.
Aparicio, Ana
Basen-Enngquist, Karen
Logothetis, Christopher J.
Gilchrist, Susan C.
Article History
Received: 27 January 2023
Accepted: 31 August 2023
First Online: 13 September 2023
Declarations
:
: This study was approved by the University of Texas MD Anderson Cancer Center Institutional Review Board.
: Not applicable.
: AWH reports advisory board consultation for Janssen and Intellisphere, honoraria from Medscape, and travel support from Dava Oncology. WT, AA, and EK have no conflicts of interest to disclose. SCG currently is employed by Labcorp Drug Development and is a consultant for Moving Analytics which is a virtual cardiac rehabilitation program. SCG has no conflicts of interest to disclose for this manuscript. CJL reports advisory board consultation for Merck, Sharpe & Dohme, Exelixis, Bayer, and Amgen; honoraria from Bayer and Amgen; and institutional funding from Janssen, ORIC Pharmaceuticals, Novartis, and Aragon Pharmaceuticals.